BIOMAT Database Logo BIOMAT Database Logo

Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. 2001

S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Division of Infectious Diseases, University Hospital, Lausanne, Switzerland.

Resistance of human immunodeficiency virus type 1 (HIV-1) to antiretroviral agents results from target gene mutation within the pol gene, which encodes the viral protease, reverse transcriptase (RT), and integrase. We speculated that mutations in genes other that the drug target could lead to drug resistance. For this purpose, the p1-p6(gag)-p6(pol) region of HIV-1, placed immediately upstream of pol, was analyzed. This region has the potential to alter Pol through frameshift regulation (p1), through improved packaging of viral enzymes (p6(Gag)), or by changes in activation of the viral protease (p6(Pol)). Duplication of the proline-rich p6(Gag) PTAP motif, necessary for late viral cycle activities, was identified in plasma virus from 47 of 222 (21.2%) patients treated with nucleoside analog RT inhibitor (NRTI) antiretroviral therapy but was identified very rarely from drug-naïve individuals. Molecular clones carrying a 3-amino-acid duplication, APPAPP (transframe duplication SPTSPT in p6(Pol)), displayed a delay in protein maturation; however, they packaged a 34% excess of RT and exhibited a marked competitive growth advantage in the presence of NRTIs. This phenotype is reminiscent of the inoculum effect described in bacteriology, where a larger input, or a greater infectivity of an organism with a wild-type antimicrobial target, leads to escape from drug pressure and a higher MIC in vitro. Though the mechanism by which the PTAP region participates in viral maturation is not known, duplication of this proline-rich motif could improve assembly and packaging at membrane locations, resulting in the observed phenotype of increased infectivity and drug resistance.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005814 Genes, Viral The functional hereditary units of VIRUSES. Viral Genes,Gene, Viral,Viral Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral

Related Publications

S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
March 1995, The Journal of infectious diseases,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
January 2004, Current topics in medicinal chemistry,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
July 2002, Antimicrobial agents and chemotherapy,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
January 2007, Antimicrobial agents and chemotherapy,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
September 2002, Journal of virology,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
September 1991, Journal of virology,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
January 2004, Molecular pharmacology,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
August 2006, Antimicrobial agents and chemotherapy,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors.
February 1994, The Journal of antimicrobial chemotherapy,
S Peters, and M Muñoz, and S Yerly, and V Sanchez-Merino, and C Lopez-Galindez, and L Perrin, and B Larder, and D Cmarko, and S Fakan, and P Meylan, and A Telenti
The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.
July 1996, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!